Phil Jakeman
Chief Executive Officer Matchbio
Seminars
Wednesday 2nd December 2026
Insights Exchange – What Biological Features Are Still Missing From Today’s Tumour Models?
5:00 pm
- Which aspects of the tumour microenvironment remain most difficult to capture?
- How can advanced models be made more scalable and reproducible?
- What innovations will have the biggest impact on model relevance over the next five years?
- Audience Q&As
Wednesday 2nd December 2026
Evidence – Exploring the CombiCell Platform to Provides a Clinically Relevant Antigen-Biology Layer for Immunotherapy Discovery
4:20 pm
- Immunotherapy response is governed by antigen density thresholds, not binary target presence – yet discovery still relies on cell lines that sit far above clinical densities, hiding the low-density and relapse conditions where CAR-T, TCEs and multi-specifics actually fail.
- CombiCell allows display of one or more targets on cells at precise, tunable densities in minutes rather than months – spanning the full clinical range, free of genetic drift, and reaching the ultra-low densities beyond the limits of flow cytometry.
- This transforms antigen density into a controllable experimental variable across modalities, grounding in vitro discovery R&D in clinical relevant target densities
